Edward Tenthoff
Stock Analyst at Piper Sandler
(2.38)
# 2,542
Out of 4,915 analysts
179
Total ratings
41.86%
Success rate
-0.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $5.01 | +199.40% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $1.44 | +247.22% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $57.68 | +82.04% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.88 | +127.40% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.66 | +321.69% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $6.90 | +30.43% | 4 | May 29, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $10.12 | +18.58% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.58 | +84.70% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.57 | +251.25% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $9.91 | +384.36% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.61 | +53.75% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $40.41 | +93.02% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $8.73 | +243.64% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $15.71 | +186.53% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $296 | $339.80 | -12.89% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $32.15 | +114.62% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $7.54 | +762.07% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.65 | +990.91% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.18 | +327.87% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $3.61 | +454.02% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.34 | +123.88% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.81 | +268.32% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $5.58 | +186.74% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.14 | +426.32% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.45 | +244.83% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $44.07 | +27.07% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $11.54 | +2,049.05% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.77 | +4,984.75% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $14.40 | +1,150.00% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $18.70 | +135.29% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.47 | +336.84% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $2.92 | +22,301,269.86% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $598.89 | -40.89% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.52 | +8,781.58% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $469.16 | -31.15% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $36.86 | -2.32% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.38 | +1,711.59% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.84 | +17,757.14% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.26 | +4,106.35% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.51 | +270,488.24% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $554.58 | - | 11 | Feb 13, 2017 |
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $5.01
Upside: +199.40%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $1.44
Upside: +247.22%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $57.68
Upside: +82.04%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.88
Upside: +127.40%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.66
Upside: +321.69%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $6.90
Upside: +30.43%
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $10.12
Upside: +18.58%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.58
Upside: +84.70%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.57
Upside: +251.25%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $9.91
Upside: +384.36%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.61
Upside: +53.75%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $40.41
Upside: +93.02%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $8.73
Upside: +243.64%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $15.71
Upside: +186.53%
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $339.80
Upside: -12.89%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $32.15
Upside: +114.62%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $7.54
Upside: +762.07%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.65
Upside: +990.91%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $8.18
Upside: +327.87%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $3.61
Upside: +454.02%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.34
Upside: +123.88%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.81
Upside: +268.32%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $5.58
Upside: +186.74%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.14
Upside: +426.32%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.45
Upside: +244.83%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $44.07
Upside: +27.07%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $11.54
Upside: +2,049.05%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $1.77
Upside: +4,984.75%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $14.40
Upside: +1,150.00%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $18.70
Upside: +135.29%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.47
Upside: +336.84%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $2.92
Upside: +22,301,269.86%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $598.89
Upside: -40.89%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.52
Upside: +8,781.58%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $469.16
Upside: -31.15%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $36.86
Upside: -2.32%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.38
Upside: +1,711.59%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.84
Upside: +17,757.14%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.26
Upside: +4,106.35%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.51
Upside: +270,488.24%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $554.58
Upside: -